Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00830219 · ClinicalTrials.gov registry record · Phase 1
The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT00830219: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00830219 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00830219, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to compare relative bioavailability of the test formulation of ropinirole hydrochloride 0.25 mg tablets (Manufactured and distributed by TEVA Pharmaceuticals USA) with the already approved formulation REQUIP® (ropinirole hydrochloride) 0.25 mg tablets (GlaxoSmithKline) under fed conditions in healthy, adult subjects.
Interventions
- DRUG Ropinirole HCl 0.25 mg Tablets
- DRUG Requip® 0.25 mg Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2004-11 |
| Est. Completion | 2004-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00830219
The ClinicalTrials.gov registry entry for NCT00830219 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ropinirole HCl 0.25 mg Tablets is the first listed.
NCT00830219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00830219 about?
NCT00830219 is a clinical study titled "The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions". The purpose of this study is to compare relative bioavailability of the test formulation of ropinirole hydrochloride 0.25 mg tablets (Manufactured and distributed by TEVA Pharmaceuticals USA) with the already approved formulation REQUIP® (ropinirole hydrochloride) 0.25 mg tablets (GlaxoSmithKline) u...
What is the current status of trial NCT00830219?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2004-11. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00830219?
The interventions under investigation include: Ropinirole HCl 0.25 mg Tablets (DRUG), Requip® 0.25 mg Tablets (DRUG).
Who is sponsoring clinical trial NCT00830219?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.